Today we announced that the last patient has completed their last visit in our Phase 3 EFZO-FIT™ study of efzofitimod in patients with #pulmonarysarcoidosis. We look forward to sharing topline results later this quarter. Read more: bit.ly/4f5DnW4
aTyr Pharma
1,085 posts
aTyr Pharma
@aTyrNews
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.
- aTyr Pharma is pleased to announce positive data from our Phase 1b/2a clinical trial of ATYR1923 in Pulmonary Sarcoidosis patients. For more information, please click the link below: bit.ly/3A9t7GX $LIFE #ATYR1923
- Today we announced that the U.S. FDA has granted Fast Track designation for efzofitimod for the treatment of pulmonary sarcoidosis. This designation for efzofitimod underscores the need for a new therapy for patients living w/ pulmonary sarcoidosis. More: bit.ly/3PeQMfN
- Listen as aTyr’s President and CEO, Dr. Sanjay S. Shukla, speaks with John Carlin, @StopSarcoidosis advocate and host of the Sarc Fighter podcast, in Episode 65 about the upcoming Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. bit.ly/2PXOitM
- Today we announced that we have completed enrollment in the global pivotal Phase 3 EFZO-FIT™ study of #efzofitimod in patients with #pulmonarysarcoidosis, a major form of #ILD. Topline data are expected in the third quarter of 2025. For more information: bit.ly/3YeM1vc
- Today we announced findings from an interim analysis of skin assessments for 8 patients at 12 weeks in our ongoing Phase 2 EFZO-CONNECT™ study of efzofitimod in limited or diffuse SSc-ILD. Read more here: bit.ly/4mHqAg5
- DYK: More than 90% of people diagnosed with sarcoidosis will have lung involvement, which is known as #pulmonarysarcoidosis. Common symptoms of pulmonary sarcoidosis include cough, chest pain, wheezing and shortness of breath. #stopsarc #makeitvisible #Efzofitimod $LIFE
- Today we announced three poster presentations for efzofitimod at #ATS2025. Join us in person at the poster presentations or view the posters on our website once presented. Read more here: bit.ly/45kmpAn $ATYR
- Current treatment for #sarcoidosis are limited & typically include using corticosteroids to control inflammation and manage symptoms, such as cough and shortness of breath for patients w/ pulmonary sarcoidosis. aTyr is developing efzofitimod. More: bit.ly/3OrarJd
- Today we announced that we have advanced ATYR0101 to IND candidate stage for #pulmonaryfibrosis. ATYR0101 and its novel anti-fibrotic mechanism was selected to be showcased at the #ATS2025 Respiratory Innovation Summit May 16-17 in San Francisco. bit.ly/43hnneg
- We are pleased to announce that we have dosed the first patient in EFZO-FIT™, a global pivotal Phase 3 study to evaluate the efficacy and safety of efzofitimod in patients with pulmonary sarcoidosis. Learn more here: bit.ly/3LO0x4t #pulmonarysarcoidosis $LIFE
- Today we announced that $ATYR is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. Read more: bit.ly/4eibw4q
- Sarcoidosis can affect any organ in the body, and 90% or more of patients with sarcoidosis will have lung involvement ATYR1923 is working to improve outcomes in those affected by Pulmonary Sarcoidosis. More here: zcu.io/hcMi #ATYR1923 #PulmonarySarcoidosis $LIFE
- We released our Second Quarter 2025 financial results and corporate update today. To read the full earnings press release, click here: bit.ly/4mwLqh0 $ATYR
